Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade D 17.96 -1.97% -0.36
MYL closed down 1.97 percent on Monday, June 24, 2019, on 61 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical MYL trend table...

Date Alert Name Type % Chg
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -1.97%
Up 3 Days in a Row Strength -1.97%
Up 4 Days in a Row Strength -1.97%
Up 5 Days in a Row Strength -1.97%
1,2,3 Retracement Bearish Bearish Swing Setup -1.37%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.37%
Up 3 Days in a Row Strength -1.37%
Up 4 Days in a Row Strength -1.37%
1,2,3 Retracement Bearish Bearish Swing Setup -0.83%

Older signals for MYL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceutical Industry In China Pharmaceuticals Policy Active Pharmaceutical Ingredients HIV/Aids Generic Drug Healthcare Institutions Disorder Generic Pharmaceutical Products Pharmaceutical Wholesalers Drug Manufacturers Injectable Products
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 39.59
52 Week Low 16.63
Average Volume 7,664,373
200-Day Moving Average 28.9079
50-Day Moving Average 21.4146
20-Day Moving Average 17.59
10-Day Moving Average 17.669
Average True Range 0.717
ADX 39.76
+DI 17.8246
-DI 25.3093
Chandelier Exit (Long, 3 ATRs ) 17.599
Chandelier Exit (Short, 3 ATRs ) 18.781
Upper Bollinger Band 18.4082
Lower Bollinger Band 16.7718
Percent B (%b) 0.73
BandWidth 9.303013
MACD Line -0.8483
MACD Signal Line -1.2281
MACD Histogram 0.3798
Fundamentals Value
Market Cap 9.63 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 14.48
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.96
Resistance 3 (R3) 19.00 18.72 18.79
Resistance 2 (R2) 18.72 18.46 18.69 18.73
Resistance 1 (R1) 18.34 18.31 18.20 18.29 18.68
Pivot Point 18.05 18.05 17.98 18.03 18.05
Support 1 (S1) 17.67 17.80 17.53 17.63 17.24
Support 2 (S2) 17.39 17.64 17.37 17.19
Support 3 (S3) 17.01 17.39 17.13
Support 4 (S4) 16.96